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The renal collecting duct is critical in the ﬁne-tuning mechanism of
sodium homeostasis. ET, ETB receptors, and nitric oxide synthase (NOS)
are all highly expressed in the collecting duct. Our laboratory is
interested in the ET/ETB/NOS signaling mechanism regulating sodium
homeostasis and blood pressure. Utilizing collecting duct-speciﬁc
knockout mice, we found that collecting duct ET/ETB activation leads to
the stimulation of collecting duct NOS1 pathway tomediate inhibition of
sodium reabsorption via epithelial sodium channel activity, while
vascular endothelial cell ET knockout mice do not activate collecting
duct NOS1.Moreover, the collecting duct NOS1 pathway does not appear
to regulate the ET/ETB pathway. The alternative splice variant, NOS1beta,
is exclusively expressed in the collecting duct of mice. Thus far, our
experiments have not detected a sexual dimorphism in the ET/ETB/NOS
pathway in the transgenic mice. However, in rats distinct male and
female regulatory pathways of ET/ETB signaling mediated sodium
homeostasis are detected. ETA and ETB mediated natriuresis is present
in female rats, while only ETB mediates natriuresis in male rats. NOS1
speciﬁc activity is signiﬁcantly higher in female rats compared to male
rats. However, NOS1 activity in male rats is ETB dependent while NOS1
activity in female rats is independent of the ET/ETB pathway. Collecting
ducts in rats express two NOS1 variants, full-length NOS1alpha and
NOS1beta. This difference in NOS1 activity and variant expression may
mediate the sexual dimorphism observed in the ET/ETB mediated
natriuresis in rats but not seen in mice. In conclusion, the ET/ETB/NOS1
signaling pathway is critical to maintain ﬂuid and electrolyte homeosta-
sis in both males and females.
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Aging is a physiological process reﬂecting the accumulation of
changes responsible for the sequential alterations that accompany
advancing age and the associated progressive increases in the chance
of disease and death (PNAS 1991; 88; 5360). Accordingly, the
American Heart Association has identiﬁed age above 45 years in men
and above 55 years in women as an independent risk factor for
cardiovascular disease. Within the last century life expectancy in
man has doubled to more than 80 years. Increased longevity will
result in an overall shift of the world population in the decades to
come (Cardiovasc Res 2005; 66: 187) which will pose additional
challenges to healthcare providers and societies.
Endothelin-1 (ET-1), a cytokine-like pro-inﬂammatorymitogen with
vascular activity and predominant member of the endothelin peptide
family, was discovered 25 years ago at the University of Tsukuba in Japan
(Nature 1988: 332: 411). ET-1 not only has physiological functions such
as embryonic development, nociception and natriuresis, but also
contributes to disease progression –mainly via ETA receptor activation.
The prevalenceof vascular and renal disease in humans showa clear age-
dependency (Nephrol Dial Transplant 2005; 20: 485), and GFR in
humans decreases by 1% per year after age 45.
Research of the past decade has provided new insights intomolecular
mechanism underlying age-dependent changes in cardiovascular and
renal physiology (Pﬂugers Arch 2010; 460: 825). It is now well
established that cellular senescence is associated with an overall
activation and production of pro-inﬂammatory cytokines and growth
factors (including ET-1), which propagate the development of (patho)-
physiological processes such as vascular hypertrophy, cardiomyocyte
injury, renal cell injury, and sarkopenia, among others. New research
indicates that aging-associated cellular changes are not inexorable, but
that aging – similar to arterial hypertension and obesity – can be
considered a modiﬁable risk factor (JCI 2013; 123; 906), in which
molecular mediators such as peptides with cellular and vascular activity
may also be involved.
Indeed, preclinical studies targeting either cellular activity or
production of ET-1 – using ERAs or ARBs, respectively – have
demonstrated that aging-associated changes in vasculature and kidney
can indeed be reversed in part (Hypertension 2004; 44: 974; Nephrol
Dial Transplant 2006; 20: 485), suggesting that the endothelin system
plays an important role in aging physiology and cellular senescence. The
clinical implications of these ﬁnding and interventions to promote
healthy aging starting in youth will be discussed.
Supported by the NSF.
doi:10.1016/j.lfs.2013.12.035
Development of osteoarthritis-like changes in transgenic
endothelin-1 over-expressed mice
Chunyi Wena, LimCho Steven Peia, Baretella Oliverb, Sookja Kim Chungc,
Aimin Xub, ChunHoi Yana, KowngYuen Chiua, Weijia William Lua
aDepartment of Orthopaedics & Traumatology, University of Hong Kong,
Hong Kong
bDepartment of Medicine, University of Hong Kong, Hong Kong
cDepartment of Anatomy, University of Hong Kong, Hong Kong
E-mail address: paulwen@hku.hk (C. Wen)
0024-3205/© 2013 The Authors. Published by Elsevier Inc. .
Life Sciences 93 (2013) e1–e2
Contents lists available at ScienceDirect
Life Sciences
j ourna l homepage: www.e lsev ie r.com/ locate / l i fesc ie
Open access under CC BY-NC-ND license. 
Endothelin-1 (ET-1), known as a potent vasoconstrictor, has been
implicated in pathogenesis of osteoarthritis (OA). ET-1 could induce
matrix metalloproteinase 13 (MMP13) expressions by chondrocytes in
vitro. Use of Endothelin 1 receptor A antagonist,might rescueOA inmice.
Yet the direct evidence remains lackingwhether overexpressed ET-1will
lead to development of OA. Therefore, we aim to characterize the
phenotypes of the articular cartilage and subchondral bone in a
transgenic endothelial cell-speciﬁc (Tie-1 promoter) overexpressed
endothelin-1 (TET-1) mice. Male heterozygous TET-1 mice were
generated by microinjection of the ET-1 construct, which contained the
mouse ET-1 cDNAwith SV40 polyA driven by the Tie-1 promoter. TET-1
mice developed systemic hypertension with altered vascular reactivity
since 8 weeks after birth. Tibiae of male, heterozygous TET-1 mice
(n= 4) and their non-transgenic littermates (n= 4) of 35-weeks-old
were obtained. PCRwere used to conﬁrm their genotypes.Micro-CT scan
on tibiaewere performed before tissue processed towax blocks. Tibiae in
wax blockswere sectioned and histologywas studied on 5 μm-thickwax
sections. Micro-CT data showed a decrease of bone volume/tissue
volume (BV/TV, 10.9 ± 0.4%) in TET-1 mice primary spongiosa when
compared to the age- and gender-matched littermates (12.8 ± 0.5%,
p b 0.05). In contrast, therewas no signiﬁcant difference in the density of
subchondral trabecular bone (secondary spongiosa) between TET-1
mice (23.5 ± 3.6%) and their littermates (25.7 ± 1.4%, p N 0.05).It was
revealed histologically that articular chondrocytes underwent hypertro-
phic changes togetherwith thickening of calciﬁed cartilage in TET-1mice
as compared to their littermates. In summary, TET-1 mice present OA-
like changes and overexpression of ET-1 contributes to hypertrophic
changes of articular chondrocytes.
doi:10.1016/j.lfs.2013.12.036
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Background: Endothelin-1 (ET-1) is strongly implicated in cardiac
and renal pathologies both as a potent vasoconstrictor and as an inducer
of tissue remodelling and ﬁbrosis. However, ET antagonists demonstrat-
ed limited efﬁcacy in clinical trials of heart failure and hypertension.
Thus, alternative preproendothelin-1 (ppET-1) derived peptides may
contribute/interact with vasoconstrictor responses. Our aim was to
characterise ppET-1 biosynthesis and to evaluate potential interactions
with ET-1 responses. Methods and results: A combination of speciﬁc
immunoassays and HPLCwere used to characterise ppET-1 processing in
conditioned media samples from human endothelial (EA.hy 926) and
epithelial (A549) cells. Endothelin-like Domain Peptide (ELDP, ppET-1
[93–166]) was identiﬁed by immunoassay with LTQ-Orbitrap mass
spectrometer conﬁrmation. Speciﬁc ELISA for ELDP showed its release
from primary cultures of human aortic endothelial cells, which
correlated with ET-1. Blood pressure responses were investigated in
anaesthetised rats. Although synthetic ELDP alone (3 nmol/kg) had no
effect, it signiﬁcantly increased the duration of the pressor response to
ET-1 (0.3 nmol/kg, p b 0.02). On rat mesenteric resistance arteries
(rMRA), ELDP alone had no signiﬁcant vasoconstrictor effect up to
10 nM, but after pre- treatment with ET-1 (1–3 nM) produced a
concentration-dependent vasoconstriction. Pre-incubation of rMRAwith
10 nM ELDP increased the response of 1 nM ET-1 by ~5-fold (p b 0.002).
Plasma levels of ELDP, measured by sandwich immunoassay, showed a
signiﬁcant difference between untreated subjects with pre-hyperten-
sion/mild hypertension (n = 24) compared to patients with chronic
heart failure (n= 24) (6.45 ± 0.19 and 7.80 ± 0.25 fmol/ml; p b 0.001,
respectively). Conclusions: ELDP is co-secretedwith ET-1 andmodulates
its vasoconstrictor responses. ELDPmay be a useful biomarker for EDN1-
linked pathologies.
doi:10.1016/j.lfs.2013.12.037
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